NASDAQ:TARS Tarsus Pharmaceuticals (TARS) Stock Price, News & Analysis $74.29 -2.79 (-3.62%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$74.01 -0.28 (-0.38%) As of 07:13 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Tarsus Pharmaceuticals Stock (NASDAQ:TARS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tarsus Pharmaceuticals alerts:Sign Up Key Stats Today's Range$74.20▼$77.6150-Day Range$56.25▼$90.7852-Week Range$53.89▼$91.53Volume674,304 shsAverage Volume753,891 shsMarket Capitalization$3.26 billionP/E RatioN/ADividend YieldN/APrice Target$100.86Consensus RatingModerate Buy Company Overview Tarsus Pharmaceuticals, Inc. is a commercial-stage ophthalmic pharmaceutical company focused on developing and marketing treatments for eye conditions with significant unmet medical needs. The company’s lead product is XDEMVY (lotilaner ophthalmic solution) 0.25%, a prescription eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis, a common eyelid disorder associated with an infestation of Demodex mites. XDEMVY is designed to target and eliminate Demodex mites, addressing an underlying cause of the disease rather than only managing its symptoms. Tarsus markets the product in the United States through ophthalmology and eye-care channels. The company has also evaluated lotilaner and other potential therapies for additional ocular surface diseases, including conditions associated with the meibomian glands. Founded in 2016, Tarsus is headquartered in Irvine, California. The company’s operations and commercial activities have been primarily focused on the U.S. ophthalmic market. Bobak Azam, a co-founder of Tarsus, serves as the company’s president and chief executive officer.AI Generated. May Contain Errors. Read More Tarsus Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreTARS MarketRank™: Tarsus Pharmaceuticals scored higher than 67% of companies evaluated by MarketBeat, and ranked 282nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingTarsus Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 1 strong buy rating, 6 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialTarsus Pharmaceuticals has a consensus price target of $94.00, representing about 26.5% upside from its current price of $74.29.Amount of Analyst CoverageTarsus Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Tarsus Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tarsus Pharmaceuticals are expected to grow in the coming year, from ($2.40) to $0.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tarsus Pharmaceuticals is -68.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tarsus Pharmaceuticals is -68.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTarsus Pharmaceuticals has a P/B Ratio of 9.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tarsus Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted15.16% of the float of Tarsus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTarsus Pharmaceuticals has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Tarsus Pharmaceuticals has recently increased by 0.23%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTarsus Pharmaceuticals does not currently pay a dividend.Dividend GrowthTarsus Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.74 News SentimentTarsus Pharmaceuticals has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Tarsus Pharmaceuticals this week, compared to 5 articles on an average week.MarketBeat Follows2 people have added Tarsus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tarsus Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,004,227.00 in company stock.Percentage Held by Insiders9.64% of the stock of Tarsus Pharmaceuticals is held by insiders.Percentage Held by Institutions90.01% of the stock of Tarsus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tarsus Pharmaceuticals' insider trading history. Receive TARS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tarsus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TARS Stock News HeadlinesReviewing Aurora Cannabis (NASDAQ:ACB) and Tarsus Pharmaceuticals (NASDAQ:TARS)2 hours ago | americanbankingnews.comTarsus Pharmaceuticals Insider Sold Shares Worth $979,744, According to a Recent SEC FilingSeptember 19, 2026 | finance.yahoo.comWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starfighter aircraft, giving it a rare platform for high-speed flight testing, captive-carry missions and aerospace research. Its Wind Tunnel in the Sky concept exposes hardware to real high-speed atmospheric conditions, while new collaborations with Vaya Defense & Space and The Bionetics Corporation expand its reach into propulsion, hypersonic test articles and payload processing. FJET is also developing STARLAUNCH, an air-launched system targeting suborbital missions, positioning the company across testing, defense and launch.September 24 at 1:00 AM | Trading Wire (Ad)Insider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells $905,600.00 in StockSeptember 10, 2026 | insidertrades.comTarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals AcquisitionSeptember 4, 2026 | marketscreener.comMTarsus Pharmaceuticals Closes Acquisition of Alkeus PharmaceuticalsSeptember 4, 2026 | finance.yahoo.comTarsus Pharmaceuticals Completes Alkeus Acquisition; Adds Phase 3 Stargardt Disease ProgramSeptember 4, 2026 | rttnews.comInsider Selling: Tarsus Pharmaceuticals (NASDAQ:TARS) Insider Sells $339,829.86 in StockSeptember 4, 2026 | insidertrades.comSee More Headlines TARS Stock Analysis - Frequently Asked Questions How have TARS shares performed this year? Tarsus Pharmaceuticals' stock was trading at $81.88 at the beginning of the year. Since then, TARS stock has decreased by 9.3% and is now trading at $74.29. How were Tarsus Pharmaceuticals' earnings last quarter? Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) released its quarterly earnings data on Thursday, August, 6th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.24. The company earned $173.91 million during the quarter, compared to analysts' expectations of $169.65 million. Tarsus Pharmaceuticals had a negative trailing twelve-month return on equity of 13.53% and a negative net margin of 7.67%. Read the conference call transcript. When did Tarsus Pharmaceuticals IPO? Tarsus Pharmaceuticals (TARS) raised $88 million in an initial public offering on Friday, October 16th 2020. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Jefferies and Raymond James served as the underwriters for the IPO and LifeSci Capital and Ladenburg Thalmann were co-managers. Who are Tarsus Pharmaceuticals' major shareholders? Tarsus Pharmaceuticals' top institutional shareholders include BlackRock Inc. (8.96%), Jupiter Topco LLC (6.40%), Bank of America Corp DE (2.72%) and Assenagon Asset Management S.A. (2.20%). Insiders that own company stock include Bobak R Azamian, William J Phd Link, Seshadri Neervannan, Bryan Wahl, Jeffrey S Farrow, Aziz Mottiwala, Dianne C Whitfield, Andrew D Goldberg, Elizabeth Yeu Lin, Jose M Trevejo and Katherine Goodrich. View institutional ownership trends. How do I buy shares of Tarsus Pharmaceuticals? Shares of TARS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tarsus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tarsus Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings8/06/2026Today9/24/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 TARS's financial health is in the Green zone, according to TradeSmith. TARS has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:TARS CIK1819790 Webwww.tarsusrx.com Phone949-409-9820FaxN/AEmployees50Year Founded2017Price Target and Rating Average Price Target for Tarsus Pharmaceuticals$94.00 High Price Target$110.00 Low Price Target$68.00 Potential Upside/Downside+26.5%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$66.42 million Net Margins-7.67% Pretax Margin-6.49% Return on Equity-13.53% Return on Assets-8.12% Debt Debt-to-Equity Ratio0.21 Current Ratio3.20 Quick Ratio3.17 Sales & Book Value Annual Sales$606.33 million Price / Sales5.38 Cash FlowN/A Price / Cash FlowN/A Book Value$8.09 per share Price / Book9.18Miscellaneous Outstanding Shares43,883,000Free Float39,653,000Market Cap$3.26 billion OptionableOptionable Beta0.54 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:TARS) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersEveryone remembers January's silver spike. Then what?Silver is up more than 50 percent over the past year, yet interest has faded since its January record. The ...i2i Marketing Group, LLC | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredWhile SpaceX Gets the Spotlight, FJET Is Building What Comes Next!Starfighters Space (NYSE: FJET) operates the world's only commercial fleet of flight-ready Mach 2+ F-104 Starf...Trading Wire | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThey're shrinking your dollars every single monthSince 2020, the dollar has lost roughly a quarter of its buying power. A $500,000 nest egg today buys about wh...American Alternative | SponsoredI went to a party with Elon...Josh Baylin, a former Bloomberg tech reporter and ex-SAC Capital analyst, has spent weeks building a paper tra...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
